These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28530522)

  • 41. Medication Nonadherence Among Medicare Beneficiaries with Comorbid Chronic Conditions: Influence of Pharmacy Dispensing Channel.
    Iyengar RN; LeFrancois AL; Henderson RR; Rabbitt RM
    J Manag Care Spec Pharm; 2016 May; 22(5):550-60. PubMed ID: 27123916
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Comprehensive Review of Methods to Measure Oral Oncolytic Dose Intensity Using Retrospective Data.
    Slejko JF; Rueda JD; Trovato JA; Gorman EF; Betz G; Arcona S; Zacker C; Stuart B
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1125-1132. PubMed ID: 31556821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of erlotinib in daily practice: a study on adherence and patients' experiences.
    Timmers L; Boons CC; Mangnus D; Moes JE; Swart EL; Boven E; Smit EF; Hugtenburg JG
    BMC Cancer; 2011 Jul; 11():284. PubMed ID: 21722354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
    Dickson R; Bagust A; Boland A; Blundell M; Davis H; Dundar Y; Hockenhull J; Martin Saborido C; Oyee J; Ramani VS
    Pharmacoeconomics; 2011 Dec; 29(12):1051-62. PubMed ID: 21967156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.
    Lyseng-Williamson KA
    Pharmacoeconomics; 2010; 28(1):75-92. PubMed ID: 20014878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of Nondherence to Diabetes Medications Among Medicare Advantage Enrollees: Development of a Validated Risk Prediction Tool.
    Mhatre SK; Serna O; Sansgiry S; Fleming ML; Essien EJ; Sansgiry SS
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1293-1301. PubMed ID: 27783546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Effect of Opioid Use and Mental Illness on Chronic Disease Medication Adherence in Superutilizers.
    Surbhi S; Graetz I; Wan JY; Gatwood J; Bailey JE
    J Manag Care Spec Pharm; 2018 Mar; 24(3):198-207. PubMed ID: 29485952
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative Effectiveness of Rapid-Acting Insulins in Adults with Diabetes.
    Racsa PN; Meah Y; Ellis JJ; Saverno KR
    J Manag Care Spec Pharm; 2017 Mar; 23(3):291-298. PubMed ID: 28230457
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
    Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Patient Reimbursement Timing and Patient Out-of-Pocket Expenses on Medication Adherence in Patients Covered by Private Drug Insurance Plans.
    Després F; Forget A; Kettani FZ; Blais L
    J Manag Care Spec Pharm; 2016 May; 22(5):539-47. PubMed ID: 27123915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy.
    Khan I; Morris S; Hackshaw A; Lee SM
    BMJ Open; 2015 Jul; 5(7):e006733. PubMed ID: 26137881
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
    Chang CH; Lee CH; Ko JC; Chang LY; Lee MC; Wang JY; Yu CJ
    Cancer Med; 2017 Jul; 6(7):1563-1572. PubMed ID: 28639751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
    Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
    Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors.
    Seetasith A; Wong W; Tse J; Burudpakdee C
    J Med Econ; 2019 May; 22(5):414-420. PubMed ID: 30729850
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer].
    Chouaid C; Moser A; Coudray-Omnès C; Vergnenègre A
    Rev Mal Respir; 2008 Nov; 25(9):1096-103. PubMed ID: 19106905
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of pharmacy channel on adherence to oral oncolytics.
    Stokes M; Reyes C; Xia Y; Alas V; Goertz HP; Boulanger L
    BMC Health Serv Res; 2017 Jun; 17(1):414. PubMed ID: 28629454
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer.
    Ganti AK; Lin CW; Yang E; Wong WB; Ogale S
    J Manag Care Spec Pharm; 2022 Mar; 28(3):305-314. PubMed ID: 34913728
    [No Abstract]   [Full Text] [Related]  

  • 59. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.
    Fiala O; Pesek M; Finek J; Racek J; Minarik M; Benesova L; Bortlicek Z; Sorejs O; Kucera R; Topolcan O
    Neoplasma; 2016; 63(3):471-6. PubMed ID: 26952513
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.
    McHorney CA; Ashton V; Laliberté F; Germain G; Wynant W; Crivera C; Schein JR; Lefebvre P; Peterson ED
    J Manag Care Spec Pharm; 2017 Sep; 23(9):980-988. PubMed ID: 28854075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.